Skip to main content
. 2022 Dec 7;13(12):1028. doi: 10.1038/s41419-022-05472-7

Fig. 7. LV-ETS1 Exos promote omentum metastasis of ovarian cancer via integrin αvβ5/AKT/Sp1 signaling.

Fig. 7

A The results of qRT-PCR showing the mRNA levels of CCL2, CXCL5 and CD163 in peritoneal macrophages incubated with LV-ETS1 Exos and cilengitide for 48 h. B Flow cytometry analysis showing the proportion of CD163 + macrophages in peritoneal macrophages incubated with LV-ETS1 Exos and cilengitide for 48 h. C Western blotting analyses showing the protein levels of CCL2, CXCL5, AKT, p-AKT and Sp1 in peritoneal macrophages incubated with LV-ETS1 Exos and cilengitide for 48 h. D Schematic diagram of the experimental schedule. LV-ETS1 Exos and LV-GFP Exos were injected into nude mice every other day, along with cilengitide for three weeks, followed by intraperitoneal injection of A2780-Luc cells. E Representative images of metastatic luciferase signal in nude mice from indicated treatment groups at 4 weeks after injection of A2780-Luc cells. F Representative images of the omental tumor burden in nude mice from indicated treatment groups at 4 weeks after injection of A2780-Luc cells. G Graphical representation of the excised omental tumor weights in nude mice from indicated treatment groups. H Representative IHC staining of CCL2 and CXCL5 in omental tumor of indicated treatment groups. Scale bars: 50 μm at ×200 magnification. I Flow cytometry analysis showing the proportion of CD163 + macrophages in omental tumor of indicated treatment groups. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.